What is HC Wainwright’s Estimate for CTMX FY2026 Earnings?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) – Equities researchers at HC Wainwright issued their FY2026 earnings estimates for shares of CytomX Therapeutics in a research report issued on Thursday, May 15th. HC Wainwright analyst M. Kapoor forecasts that the biotechnology company will post earnings of ($0.01) per share for the year. HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for CytomX Therapeutics’ current full-year earnings is ($0.05) per share.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.09. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The business had revenue of $50.92 million during the quarter, compared to analyst estimates of $35.42 million. During the same quarter in the previous year, the business earned $0.17 EPS.

Other equities research analysts have also issued research reports about the stock. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price objective (up previously from $5.00) on shares of CytomX Therapeutics in a research note on Monday, May 12th. Piper Sandler lifted their price objective on shares of CytomX Therapeutics from $2.50 to $5.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, StockNews.com raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, May 13th.

CytomX Therapeutics Trading Up 1.5%

CTMX stock opened at $2.03 on Friday. CytomX Therapeutics has a 1 year low of $0.40 and a 1 year high of $2.55. The company has a fifty day simple moving average of $0.82 and a 200 day simple moving average of $0.89. The firm has a market cap of $163.66 million, a PE ratio of 11.94 and a beta of 1.11.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Miller Financial Services LLC bought a new position in CytomX Therapeutics in the 4th quarter worth $26,000. Traphagen Investment Advisors LLC bought a new position in CytomX Therapeutics in the 4th quarter worth $31,000. Algert Global LLC bought a new position in CytomX Therapeutics in the 4th quarter worth $35,000. Velan Capital Investment Management LP bought a new position in CytomX Therapeutics in the 4th quarter worth $36,000. Finally, Aspire Growth Partners LLC bought a new position in CytomX Therapeutics in the 4th quarter worth $42,000. Institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.